Payment overview · 2025
General Payments
$981.50
52 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Douglas Grigg, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CHICO, CA · NPI 1407371941
Verified facts
What the public records show
CMS Open Payments records show Robert Douglas Grigg, PA received $981.50 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.07 | 20.8% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.27 | 16.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.78 | 14.8% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $87.12 | 8.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.81 | 7.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.71 | 5.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.82 | 3.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.40 | 3.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.58 | 3.3% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $29.41 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.19 | 3.0% | 1 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.65 | 2.6% | 1 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $19.48 | 2.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.24 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.62 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.35 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $981.50 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $174.61 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.08 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $88.73 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $87.12 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $83.23 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.23 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.81 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.81 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $61.55 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.71 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.82 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.40 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.19 | 1 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| INFUSE Normalized: infuse |
Device | Bausch & Lomb Americas Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 421 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 75 |
| Losartan Potassium | Losartan Potassium | 227 | 66 |
| Gabapentin | Gabapentin | 202 | 60 |
| Omeprazole | Omeprazole | 196 | 69 |
| Lisinopril | Lisinopril | 191 | 59 |
| Metformin Hcl | Metformin Hcl | 150 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 50 |
| Trazodone Hcl | Trazodone Hcl | 133 | 38 |
| Montelukast Sodium | Montelukast Sodium | 130 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 36 |
| Furosemide | Furosemide | 105 | 32 |
| Simvastatin | Simvastatin | 101 | 30 |
| Azithromycin | Azithromycin | 83 | 79 |
| Alprazolam | Alprazolam | 81 | 16 |
| Famotidine | Famotidine | 81 | 30 |
| Ezetimibe | Ezetimibe | 79 | 25 |
| Ozempic | Semaglutide | 78 | 18 |
| Jardiance | Empagliflozin | 75 | 24 |
| Prednisone | Prednisone | 75 | 62 |
| Baclofen | Baclofen | 74 | 32 |
| Mounjaro | Tirzepatide | 73 | 13 |
| Potassium Chloride | Potassium Chloride | 69 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Tramadol Hcl | Tramadol Hcl | 68 | 11 |
| Sertraline Hcl | Sertraline Hcl | 65 | 17 |
| Meloxicam | Meloxicam | 63 | 23 |
| Pregabalin | Pregabalin | 61 | 20 |
| Allopurinol | Allopurinol | 59 | 19 |
| Carvedilol | Carvedilol | 59 | 17 |
| Cephalexin | Cephalexin | 58 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 18 |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Repatha Sureclick | Evolocumab | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 42 |
| Finasteride | Finasteride | 44 | 16 |
| Benazepril Hcl | Benazepril Hcl | 42 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 11 |
| Atenolol | Atenolol | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 11 |
| Eliquis | Apixaban | 38 | 13 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 13 |
| Ondansetron Odt | Ondansetron | 36 | 18 |
| Bupropion Xl | Bupropion Hcl | 34 | 12 |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | 11 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 23 |
| Azelastine Hcl | Azelastine Hcl | 26 | 18 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 22 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Valsartan | Valsartan | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $981.50 · 52 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Dexcom G6 Transmitter, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, INFUSE, INJECTAFER, LINZESS, MAVYRET, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, XDEMVY, XIFAXAN, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error